VioQuest Pharmaceuticals Announces Presentations at Annual Meeting of the American Association for Cancer ResearchBASKING RIDGE, N.J.--(BUSINESS WIRE)--Mar 18, 2008 - VioQuest Pharmaceuticals (OTCBB: VQPH) announced today that the following preclinical abstracts involving the Company's product candidate VQD-002 (triciribine phosphate monohydrate, or TCN-P, also referred to as API-2) are expected to be the subject of oral or poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:
-- "Strategies for overcoming trastuzumab resistance caused by PTEN deficiency" (Abstract #675, Drug Resistance 1: Cellular Mechanisms Session) - Poster session scheduled for Sunday, April 13, 2008 from 8:00 a.m. to 12:00 p.m.
-- "A novel intracellular signaling pathway emanating from the protein synthesis machinery regulates TORC1 activity via PKC" (Abstract #2759, Signal Transduction and Therapeutics Session) - Poster session scheduled for Monday, April 14, 2008 from 1:00 p.m. to 5:00 p.m.
-- "Stimulation of epidermal growth factor (EGFR) or HER-3 mediates resistance to MET tyrosine kinase inhibition in MET-amplified gastric cancer cells" (Abstract #4975, Novel Kinase Inhibitors Session) - Oral presentation scheduled for Tuesday, April 15, 2008 from 2:40 p.m. to 2:55 p.m.
-- "Combined dasatinib and tricribine treatment synergistically inhibits the growth of sarcoma cells" (Abstract #4038, Drug Discovery 3: Combination Strategies II Session) - Poster session scheduled for Tuesday, April 15, 2008 from 8:00 a.m. to 12:00 p.m.
-- "Mechanism of AKT inhibitor-induced feedback phosphorylation of AKT" (Abstract #3570, Small G Proteins, Lipid Signaling, and mTOR Session) - Poster session scheduled for Tuesday, April 15, 2008 from 8:00 a.m. to 12:00 p.m.
-- "The Rictor-mTOR (TORC2) complex regulates myogenic differentiation" (Abstract #3566, Small G Proteins, Lipid Signaling, and mTOR Session) - Poster session scheduled for Tuesday, April 15, 2008 from 8:00 a.m. to 12:00 p.m.
-- "MicroRNA expression signature in human ovarian cancer: miRNA-214 inhibits apoptosis by targeting the PTEN/Akt pathway" (Abstract #5017, Cancer Genomics 4: MicroRNA Profiling I Session) - Poster session scheduled for Wednesday, April 16, 2008 from 8:00 a.m. to 12:00 p.m.
Abstracts and information about the AACR and its Annual Meeting may be found at www.aacr.org.
VQD-002 (triciribine phosphate monohydrate, or TCN-P, also referred to as API-2), a tricyclic nucleoside that inhibits the activation of Akt, has demonstrated anti-tumor activity against a wide spectrum of cancers in preclinical and clinical studies. Amplification, overexpression, or activation of Akt, also named protein kinase B, have been detected in a number of human malignancies, including prostate, breast, ovarian, colorectal, pancreatic, and hematologic cancers. Activation of Akt is associated with cell survival, malignant transformation, tumor invasiveness, and chemo-resistance, while inhibition of Akt activity has been shown to cause cell death. These attributes make Akt an attractive target for cancer therapy.
About VioQuest Pharmaceuticals
VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B; and Xyfid(TM) (1% topical uracil), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses.
Further information about VioQuest can be found at www.vioquestpharm.com.
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations of VioQuest's product candidates, as well as the potential role these product candidates may play in the treatment of cancers. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include VioQuest's need for additional capital to fund its clinical development programs, the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Posted: March 2008